Both Serum Apolipoprotein B and the Apolipoprotein B/Apolipoprotein A-I Ratio Are Associated with Carotid Intima-Media Thickness

Huang, Fei; Liu, Yang; Xu, Bo; Bi, Yufang; Xu, Min; Xu, Yu; Lu, Jieli; Liu, Yu; Dai, Meng; Zhou, Wenzhong; Wang, Weiqing; Chen, Yuhong

doi:10.1371/journal.pone.0054628

Cited by 31 publications

(33 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our finding was concordant to those of Huang et al who found that both apoB levels and apoB/apoA-I ratio were associated to increased CIMT (34). As reported by Dahlen et al we also observed that high apoB/apoA-I ratio, and not serum lipid profile, were associated with increased CIMT (35).…”

Section: Discussionsupporting

confidence: 92%

Association of Carotid Intima-Media Thickness With Leptin and Apolipoprotein B/Apolipoprotein a-I Ratio Reveals Imminent Predictors of Subclinical Atherosclerosis in Psoriasis Patients

Asha

Sharma

Singal

et al. 2014

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

Summary: Psoriasis patients are often susceptible to cardiovascular diseases (CVD), including atherosclerosis. Traditional markers (biochemical and inflammatory) and diagnostic tools could detect occlusive but not subclinical atherosclerosis. Carotid intima-media thickness (CIMT), has recently been recognised as a non invasive diagnostic tool for identification of premature atherosclerosis. Therefore we evaluated 80 psoriasis patients and 80 age sex matched healthy controls for serum leptin levels and apolipoprotein B/apolipoprotein A-I ratio (apoB/apoA-I ratio) in relation with CIMT of carotid artery. Carotid intima-media thickness and carotid plaques were simultaneously measured by carotid sonography. Serum concentration of leptin and apolipoprotein were measured using enzyme-linked immuno sorbent assay (ELISA) and nephelometry respectively. Raised CIMT correlated to age of onset of the disease, serum leptin and apoB/apoA-I ratio in psoriasis patients. Taking into account, values that were above the 75 percentile of the three markers (leptin, apoB/apoA-I ratio and CIMT) the odds ratio was 4.26 (2.06-8.80 CI). Leptin and apoB/apoA-I ratio showed significant cumulative association with CIMT. Results of predictive analysis supports measurement of CIMT along with estimation of serum leptin and apoB/apoA-I ratio for prediction of premature atherosclerosis in psoriasis patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Association of Carotid Intima-Media Thickness With Leptin and Apolipoprotein B/Apolipoprotein a-I Ratio Reveals Imminent Predictors of Subclinical Atherosclerosis in Psoriasis Patients

Asha

Sharma

Singal

et al. 2014

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

show abstract

“…For example, levels of ApoB have been associated with the increased carotid intima-media thickness, (Huang et al 2013) and LDL/HDL is an independent predictor of vulnerable coronary plaque (Fujihara et al 2013). PAI-1, a principal inhibitor of fibrinolysis, is induced in thrombotic, fibrotic, and cardiovascular diseases, which in turn primarily afflict the older population.…”

Section: Discussionmentioning

confidence: 99%

Synergistic in vitro antioxidant activity and observational clinical trial of F105, a phytochemical formulation includingCitrus bergamia, in subjects with moderate cardiometabolic risk factors

Babish¹,

Dahlberg

et al. 2016

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

Abstract:We examined the clinical safety and efficacy of F105 in 11 subjects with moderate dyslipidemia. F105 is a combination of bergamot fruit extract (Citrus bergamia, BFE) and 9 phytoextracts selected for their ability to improve the antioxidant and anti-inflammatory activity of BFE. In vitro F105 exhibited a synergistic inhibition of oxygen radical absorbing capacity, peroxynitrite formation, and myeloperoxidase activity. Following 12 weeks of F105 daily, no treatment-related adverse events or changes in body mass were seen. Statistically significant changes were noted in total cholesterol (−7.3%), LDL-cholesterol (−10%), non-HDL cholesterol (−7.1%), cholesterol/HDL (−26%), and apolipoprotein B (−2.8%). A post hoc analysis of 8 subjects with HbA1c > 5.4 and HOMA-IR score > 2 or elevated triglycerides revealed additional statistically significant changes in addition to those previously observed in all subjects including triglycerides (−27%), oxLDL (−19%), LDL/HDL (−25%), triglycerides/HDL (−27%), oxLDL/HDL (−25%), and PAI-1 (−37%). A follow-up case report of a 70-year-old female patient, nonresponsive to statin therapy and placed on F105 daily, demonstrated improved cardiometabolic variables over 12 weeks similar to the subgroup. In summary, F105 was clinically well-tolerated and effective for ameliorating dyslipidemia in subjects with moderate cardiometabolic risk factors, particularly in the individuals with HbA1c > 5.4%.Key words: cardiometabolic disease, bergamot, antioxidant, myeloperoxidase, oxidized LDL, dyslipidemia, HbA1c. Résumé :Les auteurs ont examiné la sécurité et l'efficacité cliniques du F105 chez 11 sujets présentant une dyslipidémie modérée. Le F105 est une combinaison d'extrait de bergamote (Citrus bergamia, EB) et 9 extraits végétaux sélectionnés pour leur capacité à améliorer l'activité antioxydante et anti-inflammatoire de l'EB. In vitro, le F105 montrait une inhibition synergique de la capacité d'absorption des radicaux d'oxygène, de formation de peroxynitrite et de l'activité myéloperoxydase. Après 12 semaines d'administration quotidienne de F105, aucun effet secondaire indésirable relié au traitement ou changements de poids corporels n'étaient observés. Des changements statistiquement significatifs ont été notés quant au cholestérol total (−7,3 %), LDL-cholestérol (−10 %), non-HDL-cholestérol (−7,1 %), cholestérol/HDL (−26 %) et apolipoprotéine B (−2,8 %). Une analyse post hoc de 8 sujets présentant une HbA1c > 5.4 et un indice HOMA-IR >2 ou des triglycérides élevés a révélé des changements additionnels statistiquement significatifs en plus de ceux précédemment observés chez tous les sujets incluant les triglycérides (−27 %), oxLDL (−19 %), LDL/HDL (−25 %) triglycérides/HDL (−27 %), oxLDL/HDL (−25 %), et PAI-1 (−37 %). Une étude de cas de suivi d'une patiente de 70 ans, ne répondant pas à la thérapie par les statines et traitée au F105 quotidiennement, a démontré amélioration des variables cardiométaboliques pendant les 12 semaines similaire au sous-groupe. En résumé, le F105 est bie...

show abstract

“…It should be emphasized that only the apo B and the apo B/apo A-I ratio remained significantly associated after the adjustment for traditional risk factors (46). Similarly, the association of the same parameters with the media-intima thickness suggest they may be early predictors of atherosclerosis (48).…”

Section: Apolipoproteinsmentioning

confidence: 95%

“…In fact, several investigators confirmed its usefulness in the prediction of cardiovascular events (46). Apo A and B are easy to be measured and showed to be useful in the prediction of cardiovascular events in some studies (45)(46)(47)(48). The meta-analysis carried out with 23 studies showed that the greatest concentrations of apo B determined a relative risk of 1.99 for events, whereas the lowest levels of apo A-I raised the risk in 62% (47).…”

Section: Apolipoproteinsmentioning

confidence: 96%

Reassessing lipid metabolism and its potentialities in the prediction of cardiovascular risk

Silva

Almeida-Pititto

Ferreira

2015

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

There are numerous particles, enzymes, and mechanisms in the lipid metabolism that are involved in the genesis of cardiovascular disease (CVD). Given its prevalence in populations and its impact on mortality, it is relevant to review the lipid metabolism as it may potentially provide subsidies to better prediction. This article reviews the importance of traditional cardiovascular risk factors and comments on the potential of novel lipid biomarkers involved in the physiopathology of CVD. The Framingham cohorts proved the role of traditional risk factors (physical inactivity, smoking, blood pressure, total cholesterol, LDL-C, HDL-C, plasma glucose) in the prediction of cardiovascular events. However, a significant number of individuals that suffer from a cardiovascular event has few or none of these factors. Such finding indicates the need for new biomarkers able to identify plaques that are more susceptible to rupture. Some of bloodstream biomarkers related to lipid metabolism are modified LDL particles, apolipoprotein AI (apo AI), apolipoprotein B, lipoprotein (a) [Lp (a)], cholesteryl ester transfer protein (CETP), subtypes of LDL and HDL particles, and lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ). These factors participate in the atherosclerotic process, and are abnormal in individuals at high risk, or in those who suffered from a cardiovascular event. Lp (a) determination is already employed in clinical practice and should be included as a reference parameter for CVD monitoring. Furthermore, there are expectations for wider use of apo B, non-HDL cholesterol and total cholesterol / HDL-C determination to improve cardiovascular risk assessment. Arch Endocrinol Metab. 2015;59(2):171-80

show abstract

Both Serum Apolipoprotein B and the Apolipoprotein B/Apolipoprotein A-I Ratio Are Associated with Carotid Intima-Media Thickness

Cited by 31 publications

References 28 publications

Association of Carotid Intima-Media Thickness With Leptin and Apolipoprotein B/Apolipoprotein a-I Ratio Reveals Imminent Predictors of Subclinical Atherosclerosis in Psoriasis Patients

Association of Carotid Intima-Media Thickness With Leptin and Apolipoprotein B/Apolipoprotein a-I Ratio Reveals Imminent Predictors of Subclinical Atherosclerosis in Psoriasis Patients

Synergistic in vitro antioxidant activity and observational clinical trial of F105, a phytochemical formulation includingCitrus bergamia, in subjects with moderate cardiometabolic risk factors

Reassessing lipid metabolism and its potentialities in the prediction of cardiovascular risk

Contact Info

Product

Resources

About